Regencell Bioscience Holdings Limited (NasdaqCM: RGC)
Health Care · Pharmaceuticals · HK
$5.50
+0.92% today · -59.1% 1Y
Regencell Bioscience Holdings Limited (NasdaqCM: RGC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.70B and employs 10 people.
Over the last twelve months the share price has lost 59.1%, trading between 4.51 and 69.00.
Tweenvest scores Regencell Bioscience Holdings Limited across four factors: quality 26/100. Its strongest factor is quality.
RGC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.70B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 1.49
- 52-week high
- $69.00
- 52-week low
- $4.51
- Avg volume (3M)
- —
- Shares outstanding
- 495.47M
- Employees
- 10
- Next earnings
- —
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
- ISIN
- KYG7487R1002
- Founded
- 2014
- Listed since
- Jul 16, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.